Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | IDE | P14735 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.59 |
| ▸ | HLCS | P50747 | 2/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153169 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL383254 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL18257230 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12551857 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL565479 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16913029 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL25417015 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10171661 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL565248 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22975316 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2807154-B1 | AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2015-12-23 | — | — | EP | claimed |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-01-01 | — | — | US | claimed |
| EP-2807154-A1 | AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2014-12-03 | — | — | EP | claimed |
| WO-2013110433-A1 | AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-01 | — | — | WO | claimed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10413621-B2 | Composition and methods for imaging cells | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| EP-1567522-A1 | PYRIMIDINE COMPOUNDS | Cyclacel Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005067644-A2 | CONJUGATED SMALL MOLECULES | AMBIT BIOSCIENCES CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050153371-A1 | Conjugated small molecules | AMBIT BIOSCIENCES CORPORATION | 2005-07-14 | — | — | US | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TDP1 4176/4885MEN1 1309/4885ABL1 839/4885 |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | PCNA, CDKN1A, CCNC | TDP1 1163/4885MEN1 1129/4885ABL1 835/4885 |
| US-10413621-B2 | Composition and methods for imaging cells | MCL1, TP53, HNRNPAB | TDP1 3017/4885MEN1 413/4885ABL1 2926/4885 |
| US-20050153371-A1 | Conjugated small molecules | ERBB2, ALK, ACP1 | TDP1 3880/4885MEN1 4141/4885ABL1 12/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | TDP1 324/4885MEN1 3957/4885ABL1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.